Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Globenewswireยท2025-07-30 05:15
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibilitySandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary pl ...